FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer
Season 5, Episode 36, Aug 26, 2021, 06:50 PM
Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.